## 12-Aminododecanoic Acid: A Building Block for Research
**12-Aminododecanoic acid (12-ADA)** is a **fatty amino acid**, meaning it contains both a long hydrocarbon chain (12 carbons) characteristic of fatty acids, and an amino group (-NH2) typical of amino acids. This unique structure makes it a versatile compound with several important research applications.
**Here's why it's important:**
* **Precursor for polyamides and other polymers:** 12-ADA is a key building block in the synthesis of **polyamides**. These polymers are known for their strength, durability, and resistance to heat, making them valuable in applications like textiles, fibers, and engineering plastics.
* **Synthesis of biologically active compounds:** 12-ADA can be used to synthesize various **biologically active compounds**, such as:
* **Surfactants:** Its amphiphilic nature (both hydrophobic and hydrophilic components) makes it useful in creating detergents and emulsifiers.
* **Pharmaceuticals:** It can be incorporated into drug molecules to enhance their properties, like solubility and biocompatibility.
* **Biomaterials:** Its biocompatibility makes it a valuable component in creating biodegradable polymers for medical implants and tissue engineering.
* **Model system for studying protein folding:** The hydrophobic tail and amino group allow 12-ADA to mimic the behavior of **amino acids in proteins**, making it a valuable tool to study protein folding and stability in simpler model systems.
* **New materials development:** Researchers are exploring 12-ADA's potential in creating **novel materials** with unique properties. This includes self-assembling systems, nanomaterials, and biocompatible materials.
**Overall, 12-aminododecanoic acid is a versatile compound that plays a crucial role in research across multiple disciplines, including:**
* **Chemistry:** Polymer science, organic synthesis
* **Biology:** Biomaterials, drug development, protein folding studies
* **Materials science:** New materials development
Its diverse applications make it a promising area for continued research and development, leading to advancements in various industries.
12-aminododecanoic acid: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
12-aminododecanoic acid : An omega-amino fatty acid that is dodecanoic acid in which one of the terminal amino hydrogens has been replaced by an amino group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 69661 |
| CHEMBL ID | 371701 |
| CHEBI ID | 42025 |
| SCHEMBL ID | 35594 |
| MeSH ID | M0133601 |
| Synonym |
|---|
| einecs 211-754-7 |
| omega-aminododecanoic acid |
| 12-aminododecanoic acid |
| 12-aminolauric acid |
| ccris 6171 |
| 12-amino-dodecanoic acid |
| LMFA01100005 |
| 12-aminododecanoic acid, 95% |
| NCGC00164406-01 |
| 693-57-2 |
| A0932 |
| CHEMBL371701 |
| AKOS000121401 |
| unii-9042rp777g |
| ec 211-754-7 |
| 9042rp777g , |
| dodecanoic acid, 12-amino- |
| FT-0607230 |
| nh2-(ch2)11-cooh |
| 12-aminododecanic acid |
| SCHEMBL35594 |
| .lambda.-aminolauric acid |
| .omega.-aminolauric acid |
| .omega.-aminododecanoic acid |
| aminododecanoic acid, omega- |
| 5-nitro-naphthalene-1-carboxylicacidethylester |
| mfcd00008153 |
| CHEBI:42025 |
| omega-aminolauric acid |
| DTXSID90883480 |
| E76112 |
| AS-16036 |
| h-adod(12)-oh |
| BCP29358 |
| 12-aminolauric acid;h-12-ado-oh;nh2-(ch2)11-cooh;dodecanoicacid pound not12-amino- |
| Q27271277 |
| 12-aminododecanoic acid 100 microg/ml in acetonitrile:acetic acid |
| 25768-33-6 |
| EN300-21176 |
| CS-0158382 |
| BP-28234 |
| Role | Description |
|---|---|
| bacterial metabolite | Any prokaryotic metabolite produced during a metabolic reaction in bacteria. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| omega-amino fatty acid | Any fatty acid n atoms long having an amino substituent at position n (omega). |
| medium-chain fatty acid | Any fatty acid with a chain length of between C6 and C12. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| AR protein | Homo sapiens (human) | Potency | 44.6684 | 0.0002 | 21.2231 | 8,912.5098 | AID588515 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 10.0000 | 0.0023 | 19.5956 | 74.0614 | AID651743 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID255583 | Percent inhibition of CD40 expression in BCL1 cells treated with 10 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| AID255581 | Percent inhibition of CD40 expression in BCL1 cells treated with 3 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| AID255579 | Percent inhibition of CD40 expression in BCL1 cells treated with 1 uM peptide nucleic acid (PNA)conjugate; n=3 | 2005 | Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21 | Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.84) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||